MDL-28170

Catalog No.S7394 Batch:S739402

Technical Data

Formula	C₂₂H₂₆N₂O₄
Molecular Weight	382.45	CAS No.	88191-84-8
Solubility (25°C)*	In vitro	DMSO	78 mg/mL (203.94 mM)
		Ethanol	6 mg/mL (15.68 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

MDL-28170 (Calpain Inhibitor III) is a potent and selective calpain inhibitor of calpain that penetrates the blood-brain barrier and inhibits brain cysteine protease activity after systemic administration. MDL-28170 is also an inhibitor of γ-secretase.

Targets

calpain ^[1]

Secretase ^[2]

In vitro

MDL28170 significantly enhances Schwann cells (SCs) survival in vitro in response to oxidative stress induced by application of H₂O₂, without reducing LDH release.^[3]

In vivo

MDL 28170 is a calpain inhibitor that protects against cortical neuronal damage even if the treatment is delayed until 3 h after reperfusion. However, the neuroprotective effect of this agent is less pronounced in the hippocampal CA1 sector.^[1]

Density

g/mL

Protocol (from reference)

Cell Assay:^{^[3]}	Cell lines Schwann cells Concentrations 50 nM, 500 nM, 5 μM, 50 μM Incubation Time 4 h Method To test the ability of MDL28170 to inhibit H2O2-mediated necrosis. Cells are treated with MDL28170 (50 nM, 500 nM, 5 μM, or 50 μM). After 1 h of drug pretreatment, fresh solution of drugs and H2O2 is added to the cells for the duration of the experiment. After 3 h of exposure the number of live or dead cells is assayed.
Animal Study:^{^[1]}	Animal Models Male Mongolian gerbils Dosages 50 mg/kg Administration IP

Cell Assay:^{^[3]}

Cell lines
Schwann cells
Concentrations
50 nM, 500 nM, 5 μM, 50 μM
Incubation Time
4 h
Method
To test the ability of MDL28170 to inhibit H2O2-mediated necrosis. Cells are treated with MDL28170 (50 nM, 500 nM, 5 μM, or 50 μM). After 1 h of drug pretreatment, fresh solution of drugs and H2O2 is added to the cells for the duration of the experiment. After 3 h of exposure the number of live or dead cells is assayed.

Animal Study:^{^[1]}

Animal Models
Male Mongolian gerbils
Dosages
50 mg/kg
Administration
IP

References

Selleck's MDL-28170 has been cited by 8 publications

Astragaloside IV mitigates hypoxia-induced cardiac hypertrophy through calpain-1-mediated mTOR activation [ Phytomedicine, 2024, 125:155250]	PubMed: 38295664
Calpain-1 Up-Regulation Promotes Bleomycin-Induced Pulmonary Fibrosis by Activating Ferroptosis [ Am J Pathol, 2024, S0002-9440(24)00356-0]	PubMed: 39326733
Ginsenoside Rg1 attenuates diabetic vascular endothelial dysfunction by inhibiting the calpain-1/ROS/PKC-β axis [ Life Sci, 2023, 329:121972]	PubMed: 37482213
Prevention of noise-induced hearing loss by calpain inhibitor MDL-28170 is associated with upregulation of PI3K/Akt survival signaling pathway [ Front Cell Neurosci, 2023, 17:1199656]	PubMed: 37484825
Ginsenoside Rg1 ameliorates chronic intermittent hypoxia-induced vascular endothelial dysfunction by suppressing the formation of mitochondrial reactive oxygen species through the calpain-1 pathway [ J Ginseng Res, 2023, 47(1):144-154]	PubMed: 36644390
DNA damage contributes to age-associated differences in SARS-CoV-2 infection [ Aging Cell, 2022, 21(12):e13729]	PubMed: 36254583
Protective effect of Astragaloside IV on chronic intermittent hypoxia-induced vascular endothelial dysfunction through the calpain-1/SIRT1/AMPK signaling pathway [ Front Pharmacol, 2022, 13:920977]	PubMed: 35983375
Inhibiting SRC activity attenuates kainic-acid induced mouse epilepsy via reducing NR2B phosphorylation and full-length NR2B expression [ Epilepsy Res, 2022, 185:106975]	PubMed: 35907325

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.